Viewing Study NCT00265135



Ignite Creation Date: 2024-05-05 @ 12:10 PM
Last Modification Date: 2024-10-26 @ 9:21 AM
Study NCT ID: NCT00265135
Status: COMPLETED
Last Update Posted: 2014-07-03
First Post: 2005-12-13

Brief Title: A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Sponsor: Centocor Inc
Organization: Centocor Inc

Study Overview

Official Title: A Phase III Study of a Chimeric Antibody Against Interleukin-6 CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Status: COMPLETED
Status Verified Date: 2014-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to better understand the safety tolerability and distribution of CNTO 328 in the bloodstream
Detailed Description: This research study uses a type of drug called anti-IL-6 monoclonal antibody also known as CNTO 328 CNTO 328 is a new experimental drug This study is trying to better understand the safety the tolerability side effects and the distribution of the drug in the blood stream The effects of CNTO 328 in patients with renal cell carcinoma are currently unknown However recent data has shown that treatment with another anti-IL-6 monoclonal antibody reduces the symptoms of renal cell carcinoma

The study is divided in 3 parts Part 1 is the phase I portion of the study and evaluated the safety of CNTO 328 in subjects with metastatic renal cell carcinoma Part 2 and 3 will evaluate efficacy and safety of the drug in this patient population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
C0328T01 OTHER Centocor None